Barcelona

• A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma Ended
  2023-505672-30-00 4 2023-02-10 Unresectable or Metastatic Melanoma
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effe … Ended
  2023-510317-26-00 4 2023-02-07 Amyotrophic Lateral Sclerosis
• Phase 3 Study to Assess Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Generalized Myasth … Ended
  2024-512258-91-00 5 2023-02-03 Generalized Myasthenia Gravis (gMG)
• Interventional Platform Study Investigating the Impact of Digital Health Solutions on Health Outcomes and Health-Care Resource Utilization i … Ended
  2023-504342-55-00 10 2023-02-02 Cohort A: • Metastatic non-small cell lung carcinoma (mNSCLC) • Exten
• Multicenter, Open-label, Single arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan Tolerance in Patients with Metastatic Triple-N … Ended
  2024-514060-10-00 4 2023-02-02 Advanced triple-negative breast cancer (TNBC), Advanced HR[+]/HER2[–]
• STRIDES - A Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia Ended
  2022-501004-10-00 10 2023-01-30 Spinocerebellar Ataxia type-3 (SCA3)
• A 12-month, randomized, single-blind, placebo-controlled exposure-response study of TCD601 (siplizumab) in new onset type 1 diabetes patient … Ended
  2023-506837-31-00 4 2023-01-27 New onset type I diabetes
• A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects … Ended
  2024-514761-19-00 5 2023-01-25 Idiopathic Pulmonary Fibrosis
• A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran … Ended
  2023-503793-20-00 5 2023-01-18 Prevention of ischemic stroke in patients post acute non-cardioembolic
• A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activ … Ended
  2022-500116-18-00 3 2023-01-09 Advanced Solid Tumors
• Phase 3 Study of Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B (B-Well 1) Ended
  2023-504239-41-00 5 2023-01-09 Hepatitis B, Chronic
• Phase 2 Study of MORAb-202 in Previously Treated Metastatic NSCLC AC Ended
  2023-504112-15-00 4 2023-01-04 Metastatic Non-Small Cell Lung Cancer
• An Open Label Study to Evaluate A3907 in Adults with Primary Sclerosing Cholangitis (PSC) Ended
  2022-500790-14-00 4 2023-01-02 Primary Sclerosing Cholangitis (PSC)
• Relatlimab + Nivolumab in Pediatric and Young Adult Lymphomas (RELATIVITY-069) Ended
  2023-503715-14-00 9 2022-12-29 Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lym
• An extension of the orchestra (PD0053) study to learn how safe minzasolmin is and if it works long-term in participants with Parkinson’s dis … Ended
  2022-500424-30-00 4 2022-12-28 Parkinson’s disease
• Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 year … Ended
  2024-512095-35-00 9 2022-12-27 Relapsed or refractory neuroblastoma and other solid tumors (including
• A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activi … Ended
  2022-500115-39-00 1 2022-12-23 Advanced Solid Tumors
• Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin followed by Oral Ibrexafungerp versus I … Ended
  2024-511755-18-00 5 2022-12-23 Invasive Candidiasis/ Candidemia
• Phase 2b Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis Ended
  2024-514975-16-00 4 2022-12-22 Non-infectious, Intermediate-, Posterior- or Pan-uveitis
• An Open-Label Extension Study for Patients who Previously Completed Study ISEE2008 (GATHER2) Ended
  2024-515185-13-00 5 2022-12-21 geographic atrophy
• A Phase 2 double-blind, randomized, placebo-controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participant … Ended
  2023-509078-45-00 4 2022-12-19 Multiple sclerosis
• Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION) Ended
  2023-508528-36-00 5 2022-12-16 Resected squamous cell carcinoma of the head and neck
• Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients with Platinum-Resistant Ep … Ended
  2024-513230-38-00 5 2022-12-15 Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peri
• A study to Evaluate AB308 in Combination with AB122 in Participants with Advanced Malignancies (ARC-12) Ended
  2024-511116-25-00 1 2022-12-13 Multiple Myeloma

Showing 2,929–2,952 of 3,391 trials